2026-08-05T15:43:24Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/270342025-12-18T12:57:34Zcom_20.500.12105_19586com_20.500.12105_2202col_20.500.12105_19587

00925njm 22002777a 4500 dc Ibanez, Borja author Latini, Roberto author Rossello, Xavier author Dominguez-Rodriguez, Alberto author Fernández-Vazquez, Felipe author Pelizzoni, Valentina author Sánchez, Pedro L author Anguita, Manuel author Barrabés, José A author Raposeiras-Roubín, Sergio author Pocock, Stuart author Escalera, Noemí author Staszewsky, Lidia author Pérez-García, Carlos Nicolás author Díez-Villanueva, Pablo author Pérez-Rivera, Jose-Angel author Prada-Delgado, Oscar author Owen, Ruth author Pizarro, Gonzalo author Caldes, Onofre author Gómez-Talavera, Sandra author Tuñón, José author Bianco, Matteo author Zarauza, Jesus author Vetrano, Alfredo author Campos, Ana author Martínez-Huertas, Susana author Bueno, Héctor author Puentes, Miguel author Grigis, Giulietta author Bonilla-Palomas, Juan L author Marco, Elvira author González-Juanatey, José R author Bangueses, Roi author González-Juanatey, Carlos author García-Álvarez, Ana author Ruiz-García, Juan author Carrasquer, Anna author García-Rubira, Juan C author Pascual-Figal, Domingo author Tomás-Querol, Carlos author San Román, J Alberto author Baratta, Pasquale author Agüero, Jaume author Martín-Reyes, Roberto author Colivicchi, Furio author Ortas-Nadal, Rosario author Bazal, Pablo author Cordero, Alberto author Fernández-Ortiz, Antonio author Basso, Pierangelo author González, Eva author Poletti, Fabrizio author Bugani, Giulia author Debiasio, Marzia author Cosmi, Deborah author Navazio, Alessandro author Bermejo, Javier author Tortorella, Giovanni author Marini, Marco author Botas, Javier author de la Torre-Hernández, José M author Ottani, Filippo author Fuster, Valentín author 2025-11-13 Current guideline recommendations for the use of beta-blockers after myocardial infarction without reduced ejection fraction are based on trials conducted before routine reperfusion, invasive care, complete revascularization, and contemporary pharmacologic therapies became standard practice. We conducted an open-label, randomized trial in Spain and Italy to evaluate the effect of beta-blocker therapy, as compared with no beta-blocker therapy, in patients with acute myocardial infarction (with or without ST-segment elevation) and a left ventricular ejection fraction above 40%. The primary outcome was a composite of death from any cause, reinfarction, or hospitalization for heart failure. In total, 4243 patients were randomly assigned to receive beta-blocker therapy and 4262 to receive no beta-blocker therapy; after exclusions, 8438 patients were included in the main analysis. During a median follow-up of 3.7 years, a primary-outcome event occurred in 316 patients (22.5 events per 1000 patient-years) in the beta-blocker group and in 307 patients (21.7 events per 1000 patient-years) in the no-beta-blocker group (hazard ratio, 1.04; 95% confidence interval [CI], 0.89 to 1.22; P = 0.63). Death from any cause occurred in 161 patients and 153 patients, respectively (11.2 vs. 10.5 events per 1000 patient-years; hazard ratio, 1.06; 95% CI, 0.85 to 1.33); reinfarction in 143 patients and 143 patients (10.2 vs. 10.1 events per 1000 patient-years; hazard ratio, 1.01; 95% CI, 0.80 to 1.27); and hospitalization for heart failure in 39 patients and 44 patients (2.7 vs. 3.0 events per 1000 patient-years; hazard ratio, 0.89; 95% CI, 0.58 to 1.38). No apparent between-group differences in safety outcomes were noted. Among patients discharged after invasive care for a myocardial infarction with a left ventricular ejection fraction above 40%, beta-blocker therapy appeared to have no effect on the incidence of death from any cause, reinfarction, or hospitalization for heart failure. (Funded by Centro Nacional de Investigaciones Cardiovasculares Carlos III and others; ClinicalTrials.gov number, NCT03596385; EudraCT number, 2017-002485-40.). N Engl J Med. 2025 Nov 13;393(19):1889-1900. NEW ENGLAND JOURNAL OF MEDICINE 40888702 https://hdl.handle.net/20.500.12105/27034 Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction.